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ABS TRACT
It has long been accepted that modern reproductive patterns are likely contributors to breast cancer
susceptibility because of their influence on hormones such as estrogen and the importance of these
hormones in breast cancer. We conducted a meta-analysis to assess whether this ‘evolutionary mis-
match hypothesis’ can explain susceptibility to both estrogen receptor positive (ER-positive) and estro-
gen receptor negative (ER-negative) cancer. Our meta-analysis includes a total of 33 studies
and examines parity, age of first birth and age of menarche broken down by estrogen receptor status.
We found that modern reproductive patterns are more closely linked to ER-positive than ER-negative
breast cancer. Thus, the evolutionary mismatch hypothesis for breast cancer can account for ER-positive
breast cancer susceptibility but not ER-negative breast cancer.
KEYWORDS : evolutionary mismatch; breast cancer heterogeneity; cancer evolution; hormone-
associated breast cancer; parity; age of first birth
INTRODUCTION
It has long been known that breast cancer is
associated with reproductive factors such as age of
menarche, parity and reproductive timing [1].
However, breast cancer is a heterogeneous disease,
and different subtypes of breast cancer have
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different risk factors [2–11]. In this review, we take an
evolutionary approach to examine how risk factors
associated with modern reproductive patterns as
opposed to those characteristic of ancestral peoples
differ with regard to estrogen receptor (ER) status.
Evolutionary approaches to health and medicine
have become increasingly prevalent over the last two
decades, [12–14], with more attention being paid
to evolutionary theory and methods in varied areas
of medicine. Evolutionary theory applies to many
aspects of cancer [15–18], including the role of
modern environments in shaping susceptibility to
cancer. ‘Evolutionary mismatch’ between ancestral
and modern conditions plays a role in a variety of
diseases including cancer [19].
Evolutionary mismatch theory and breast
cancer susceptibility
When environments change rapidly, natural selec-
tion may be too slow to adapt our phenotypes to
the new condition. The resulting mismatch can have
various consequences, including dysregulation of
cancer suppression mechanisms that increase vul-
nerability to cancer. A variety of modern ecological,
demographic and cultural changes appear to con-
tribute to cancer risk, including increased nutrition
[20], changes in reproductive patterns [21–23], popu-
lation migrations [24] and changes in cultural prac-
tices such as smoking [25]. In this article, we focus
on the association of breast cancer and modern re-
productive patterns, which are characterized by
earlier age at menarche, delayed reproduction and
lower fertility than would have been the case for
ancestral humans [21–23]. Here we define modern
societies as any societies’ post-demographic transi-
tion, where there are both low birth rates and death
rates.
Previous researchers have proposed that high
rates of breast cancer in the modern world result,
in part, from a modern reproductive pattern, with
women experiencing on the order of 300–400 men-
strual cycles while our ancestors were likely to have
experienced 100 or less [21–23]. According to this
view, the large increase in number of cycles in mod-
ern humans causes higher levels of cyclic hormone
exposure over the lifetime that made modern
women more susceptible to breast cancer than
our pre-agricultural ancestors. This aspect of breast
cancer etiology is generally accepted among epi-
demiologists [26, 27], and it is consistent with
established and commonly accepted risk factors
for breast cancer such as early menarche, low fertil-
ity, later age of first birth and later menopause [28].
In this article, we test whether mismatch between
ancestral and modern reproductive patterns is con-
sistent with breast cancer susceptibility. In particu-
lar, we examine whether the mismatch explanation is
consistent with the incidence of both estrogen re-
ceptor positive (ER-positive) and estrogen receptor
negative (ER-negative) breast cancers. Because ER-
negative breast cancers are typically insensitive to
hormones, we predict that these breast cancers
may not be associated with higher hormonal
exposures characteristic of modern reproductive
patterns.
ER status
One critical difference among breast cancer sub-
types that has long been recognized is that of estro-
gen dependent (ER-positive) versus estrogen
independent types (ER-negative). The majority of
breast cancers are ER-positive [29]. Breast tumors
are clinically defined as ER-positive if a minimum
of 10% of cells exhibit ERs (e.g. [30]), meaning that
some ER-positive tumors will have 15% ER-positive
cells and others may have 95% ER-positive cells.
Thus, ER-positive tumors are actually highly diverse
with regard to their expression of ER. This diversity
may be a result of different stages of progression or
may simply be a reflection of pre-existing differences
in ER status in normal and pre-cancerous breast can-
cer tissue [31]. Breast cancers can also be heteroge-
neous within a tumor, as is clear from results
of multiple biopsies in which different degrees of
ER positivity are observed in different regions of
the tumor [32]. ER-positive breast cancers tend
to be easier to treat because they can often be suc-
cessfully treated with aromatase inhibitors, which
block the production of estrogen or the action of
estrogen on ERs. Thus, ER status provides a way
of categorizing tumors that has proven clinical
utility.
There are also two types of ERs,  and . The 
receptor has a greater affinity for estrogen than the 
receptor, and it appears that invasive tumors have a
higher ratio of  receptors relative to  receptors
than is the case in normal breast tissue [33]. Breast
epithelial cells also have receptors for progesterone
and growth factors such as Her2/Neu. These
subtypes will not be covered in this review due to
insufficient data availability.
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METHODS
We surveyed the literature and performed several
meta-analyses to evaluate whether breast cancer
susceptibility by ER status was differentially
associated with reproductive factors including par-
ity, age of first reproduction and age of menarche
(see Appendix for methods). Age of menopause
was not included because of large methodological
differences among studies in the calculation of
menopausal age. We identified 33 studies that were
included in the final analysis, 25 of which were case–
control studies and 8 that were cohort studies.
Twenty studies were conducted in USA, and 13 were
from diverse countries worldwide. The methods for
data extraction and analysis are included in the
Appendix. The specific cutoffs used to define parity,
late age at first birth and late age at menarche varied
by study and are listed in each of the figures.
RESULTS
Parity
Parity was found to be protective against ER-positive
breast cancer (Fig. 1a; odds ratio (OR) = 0.77, 95%
confidence interval (CI) = 0.71–0.82, P< 0.001) but
not protective against ER-negative breast cancer
(Fig. 1b; OR = 1.01, 95% CI = 0.95–1.08, P = 0.69).
In other words, our meta-analysis showed that
women who had given birth to one or more children
had a lower risk of ER-positive breast cancer but
that their risk of ER-negative breast cancer was not
affected.
Age of first birth
Our meta-analysis indicated that late age of first
birth (after age 30 or 35) was associated with higher
odds of ER-positive breast cancer (Fig. 2a; OR = 1.42,
95% CI = 1.30–1.55, P< 0.001). ER-negative breast
cancer, on the other hand, was not found to be
associated with late age of first birth (Fig. 2b;
OR = 1.05, 95% CI = 0.91–1.21, P = 0.53).
Age of menarche
Late age of menarche (typical cutoff around 12
years) was found to be protective against ER-positive
breast cancer (Fig. 3a; OR = 0.85, 95% CI = 0.80–
0.90, P< 0.001). Late menarche was also associated
with a lower risk for ER-negative breast cancer
(Fig. 3b; OR = 0.90, 95% CI = 0.83–0.98, P = 0.02).
In total, each of the three aspects of modern
reproductive patterns that we examined in this
meta-analysis was significantly associated with ER-
positive breast cancer risk at P< 0.001. In contrast,
risk of ER-negative breast cancer was neither
associated with nulliparity nor late age of first birth.
For ER-negative breast cancer, only late age of me-
narche was associated with lower risk, and this effect
was weak compared with the protective effect of late
menarche on ER-positive breast cancer.
DISCUSSION
The resultsofour meta-analysis suggest that modern
reproductive patterns are consistent with
evolutionary mismatch theory for ER-positive but
not ER-negative breast cancer susceptibility.
Neither early age at first birth nor higher parity was
associated with a decrease in ER-negative breast can-
cer susceptibility. However, early menarche was
associated with increased susceptibility to both ER-
positiveand ER-negative breast cancer. It isunknown
whether early menarche simply increases global risk
ofbreast cancerorwhether the roleofpubertal timing
in breast cancer susceptibility may be more complex,
perhaps involving different mechanisms in ER-posi-
tive and ER-negative breast cancer susceptibility.
What mechanisms might underlie susceptibility
to ER-negative breast cancer?
Our finding that ER-negative breast cancer suscep-
tibility was not associated with modern reproductive
timing and parity puts a new perspective on the gen-
erally accepted view that breast cancer susceptibility
is associated with an increase in number of cycles
and higher levels of cyclic hormone exposure
[26, 27]. Our results suggest that ER-negative breast
cancer risk may involve mechanisms other than cyc-
lical hormonal exposure. Potential mechanisms
underlying ER-negative breast cancers susceptibility
include inflammation [66] and insulin resistance
[67]. Genetic factors such as BRCA1 mutations are
also associated with hormone-negative breast can-
cer risk [68], suggesting that physiological processes
more likely associated with these BRCA1 variants,
such as lower levels of DNA repair, are potential
mechanisms contributing to ER-negative breast
cancer susceptibility. Epigenetics may play an im-
portant role in ER-negative breast cancer
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susceptibility as well: Hypermethlyation of BRCA1
[69] has been found to be associated with triple nega-
tive breast cancer but not ER-positive breast cancer.
Also, increased methylation of the ER-alpha gene
has been found in BRCA-linked ER-negative breast
cancer [70], identifying a potential mechanism for
the reduced expression of the ER-receptor in these
tissues. Given that epigenetic changes are also
known to regulate ER expression [71], this suggests
that epigenetics may be important to understanding
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Figure 1. (a) Parity is associated with a lower risk of ER-positive breast cancer. (b) Parity is not associated with risk of ER-negative
breast cancer. OR was calculated using a random effects model to account for heterogeneity of study populations. The red
squares and horizontal black lines represent the ORs and 95% CIs for each study. The black diamond and its width represent the
overall effect estimate and the 95% CI. The vertical black line represents the null hypothesis (OR of 1). Premeno. = pre-meno-
pausal, Postmeno. = post-menopausal, ER = estrogen receptor, PR = progesterone receptor, TN = triple negative, HER2 = human
epidermal growth factor receptor 2, Lum. = luminal
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susceptibility to both ER-negative and ER-positive
breast cancer.
The role of epigenetics in ER expression raises
the possibility that the influence of early environ-
ment on cancer susceptibility could be mediated
by epigenetic changes. Epigenetic changes can
occur as a result of physical and social inputs
experienced by individuals throughout the life
course [72] and have lasting effects [73, 74]. For ex-
ample, stressful environments can cause
epigenetically mediated changes in the functioning
of the hypothalamic pituitary adrenal (HPA) axis and
glucocorticoid receptors [75], changes in inflamma-
tion [76] and even direct effects on tissues such as
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   McTiernan et al. [45]
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   Ursin et al. [51]
   Ursin et al. [51]
Subtotal (95% CI)
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   Ma et al. [57]
   Palmer et al. [58]
   Palmer et al. [58]
   Phipps et al. [59]
   Setiawan et al. [64]
   Setiawan et al. [64]
   Wohlfahrt et al. [62]
Subtotal (95% CI)
Total (95% CI)
Heterogeneity: Tau2 = 0.00; Chi2 = 15.45, df = 15 (p = 0.42), I2 = 3%
Test for overall effect: Z = 7.65 (p < 0.00001)
Test for subgroup differences: Chi2 = 0.83, df = 1 (p = 0.36), I2 = 0%
Heterogeneity: Tau2 = 0.03; Chi2 = 11.85, df = 8 (p = 0.16), I2 = 32%
Test for overall effect: Z = 2.56 (p = 0.01)
Population
American, premeno. <35yo
American, premeno. 35-54yo
Australian, 20-74yo
Canadian, 20-69yo
American, 20-49yo
American, 25-54yo
American, 20-54yo
American, 35-64yo
American, 35-64yo
Population
American, postmeno. >56yo
African American, 21-69yo
African American, 21-69yo
American, postmeno. 50-79yo
American, 45-75yo
American, 45-75yo
Danish, 21-64yo
Comparison
LE 19 vs GE 30
LE 19 vs GE 30
LE 19 vs GE 30
LE 20 vs GE 31
LE 21 vs GE 32
LE 19 vs GE 30
LE 19 vs GE 29
LE 19 vs GE 30
LE 19 vs GE 30
Comparison
LE 20 vs GE 35
LE 19 vs GE 30
LE 19 vs GE 30
LE 19 vs GE 30
LE 20 vs GE 31
LE 20 vs GE 31
20-24 vs GE 35
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ER+
ER+
ER+
ER+
ER+PR+
ER+
ER+
ER+PR+
ER+PR-
Type
ER+
ER+PR+
ER+PR-
ER+
ER+PR-
ER+PR+
ER+
OR (95% CI)
1.97 (1.39, 2.79)
0.83 (0.29, 2.40)
1.55 (0.69, 3.48)
0.87 (0.53, 1.43)
1.23 (0.72, 2.10)
2.60 (1.06, 6.37)
1.21 (0.51, 2.86)
1.14 (0.70, 1.86)
1.22 (0.97, 1.54)
1.32 (1.07, 1.63)
Weight
6.4%
0.7%
1.2%
3.2%
2.7%
1.0%
1.1%
3.2%
13.9%
33.5%
OR (95% CI)
1.37 (1.02, 1.84)
1.34 (0.93, 1.94)
1.45 (0.72, 2.93)
1.36 (1.10, 1.68)
1.68 (1.01, 2.80)
1.52 (1.22, 1.90)
1.63 (1.31, 2.03)
1.47 (1.32, 1.63)
Weight
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16.8%
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15.1%
15.4%
66.5%
Heterogeneity: Tau2 = 0.00; Chi2 = 2.21, df = 6 (p = 0.90), I2 = 0%
Test for overall effect: Z = 7.14 (p < 0.00001)
1.42 (1.30, 1.55) 100.0%
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Test for overall effect: Z = 0.62 (p = 0.53)
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Heterogeneity: Tau2 = 0.00; Chi2 = 7.74, df = 8 (p = 0.46), I2 = 0%
Test for overall effect: Z = 0.49 (p = 0.62)
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American, premeno. 35-54yo
Australian, 20-74yo
Canadian, 20-69yo
American, 20-49yo
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American, 35-64yo
American, 35-64yo
Population
American, postmeno. >56yo
African American, 21-69yo
American, 40-84yo
American, 45-75yo
Danish, 21-64yo
Comparison
LE 19 vs GE 30
LE 19 vs GE 30
LE 19 vs GE 30
LE 20 vs GE 31
LE 21 vs GE 32
LE 19 vs GE 30
LE 19 vs GE 29
LE 19 vs GE 30
LE 19 vs GE 30
Comparison
LE 20 vs GE 35
LE 19 vs GE 30
LE 19 vs GE 30
LE 20 vs GE 31
20-24 vs GE 35
Type
ER-
ER-
ER-
ER-
ER-PR-
ER-
ER-
ER-PR-
ER-PR+
Type
ER-
ER-PR-
TN
ER-PR-
ER-
OR (95% CI)
1.21 (0.39, 3.78)
1.11 (0.71, 1.73)
1.25 (0.39, 4.01)
0.55 (0.23, 1.32)
0.56 (0.30, 1.06)
0.83 (0.29, 2.39)
1.68 (0.78, 3.61)
1.17 (0.64, 2.13)
0.91 (0.68, 1.22)
0.95 (0.79, 1.15)
Weight
1.6%
10.6%
1.5%
2.7%
5.2%
1.9%
3.6%
5.8%
24.5%
57.4%
OR (95% CI)
1.21 (0.52, 2.81)
1.47 (0.94, 2.29)
1.05 (0.53, 2.07)
1.32 (0.87, 2.00)
0.93 (0.62, 1.40)
1.19 (0.95, 1.48)
Weight
2.9%
10.5%
4.5%
12.2%
12.4%
42.6%
Heterogeneity: Tau2 = 0.00; Chi2 = 2.62, df = 4 (p = 0.62), I2 = 0%
Test for overall effect: Z = 1.52 (p = 0.13)
1.05 (0.91, 1.21) 100.0%
Age at First Birth, ER- Breast Cancer
A
B
Figure 2. (a) Later age of first birth is associated with a higher risk of ER-positive breast cancer. (b) Later age of first birth is not
associated with risk of ER-negative breast cancer. OR was calculated using a random effects model to account for heterogeneity of
study populations. The red squares and horizontal black lines represent the ORs and 95% CIs for each study. The black diamond
and its width represent the overall effect estimate and the 95% CI. The vertical black line represents the null hypothesis (OR of 1).
Premeno. = pre-menopausal, Postmeno. = post-menopausal, cont. = continuous, ER = estrogen receptor, PR = progesterone
receptor, TN = triple negative, HER2 = human epidermal growth factor receptor 2, Lum. = luminal, LE = less than or equal to,
GE = greater than or equal to
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mammary tissues [77]. Whether epigenetic changes
in these processes are specific to ER-negative breast
cancer requires further study.
Applications to other cancers
Like breast cancer, ovarian cancer has both ER-posi-
tive and ER-negative subtypes. ER-negative ovarian
cancer is associated with lower rates of survival [78]
compared with ER-positive ovarian cancer. Breast
and ovarian cancer share susceptibility genes such
as BRCA1/2 [79] and RAD51C [80], making it likely
that they may share mechanisms underlying cancer
risk. Some evidence suggests that the prevalence of
ovarian cancer risk factors differ by subtype [81],
though this study did not examine whether modern
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Heterogeneity: Tau2 = 0.01; Chi2 = 78.55, df = 36 (p < 0.0001), I2 = 54%
Test for overall effect: Z = 5.19 (p < 0.00001)
Test for subgroup differences: Chi2 = 0.05, df = 1 (p = 0.83), I2 = 0%
Heterogeneity: Tau2 = 0.02; Chi2 = 68.68, df = 30 (p < 0.0001), I2 = 56%
Test for overall effect: Z = 4.28 (p < 0.0001)
Population
Chinese, 20-70yo
Chinese, 20-70yo
American, 20-44yo
American, 20-44yo
Australian, 20-74yo
Canadian, premeno. 25-55yo
Canadian, postmeno. >55yo
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American, <57yo
Canadian, premeno. <55yo
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American, 20-74yo
American, 20-74yo
Canadian, 20-69yo
American, 20-49yo
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American, 25-54yo
American, 20-74yo
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Swedish, postmeno. 50-70yo
Swedish, postmeno. 50-70yo
American, 40-80yo
American, 40-80yo
Chinese, 21-85yo
Chinese, 21-85yo
Polish, 20-74yo
Polish, 20-74yo
American
Japanese, >25yo
African American, 20-64yo
Population
Japanese, 40-59yo
American, postmeno. 50-79yo
American, 55-69yo
American, 55-69yo
American, 45-75yo
American, 45-75yo
Comparison
LE 13 vs GE 17
LE 13 vs GE 17
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 14
LE 11 vs GE 14
LE 11 vs GE 14
Cont. (2yr increments)
Cont. (2yr increments)
LE 12 vs GE 14
LE 12 vs GE 14
LE 11 vs GE 12
LE 11 vs GE 12
LE 11 vs GE 15
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 13
LE 13 vs GE 14
LE 14 vs GE 17
12-13 vs GE 16
12-13 vs GE 16
LE 11 vs GE 14
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
Cont. (2yr increments)
Cont. (2yr increments)
LE 12 vs GE 15
Cont. (2yr increments)
LE 12 vs GE 13
Comparison
Cont. (1yr increments)
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 15
LE 12 vs GE 15
Type
ER+PR-
ER+PR+
ER+PR-
ER+PR+
ER+
ER+PR+
ER+PR+
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Lum. A
ER+
ER+
ER+PR-
ER+PR+
ER+
ER+PR+
ER+PR-
ER+PR+
ER+
Lum. A
ER+
ER+PR+
ER+PR-
ER+PR+
ER+PR-
Lum. B
Lum. A
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Lum. A
ER+ 
ER+
ER+
Type
ER+
ER+
ER+PR+
ER+PR-
ER+PR+
ER+PR-
OR (95% CI)
0.79 (0.52, 1.20)
0.66 (0.53, 0.82)
0.93 (0.63, 1.38)
0.77 (0.63, 0.94)
1.03 (0.55, 1.94)
0.84 (0.64, 1.10)
0.49 (0.31, 0.77)
0.60 (0.42, 0.85)
0.87 (0.75, 1.01)
1.48 (1.12, 1.96)
0.78 (0.61, 1.00)
1.25 (0.61, 2.57)
0.67 (0.50, 0.90)
0.77 (0.47, 1.26)
0.60 (0.42, 0.86)
0.80 (0.59, 1.08)
0.90 (0.47, 1.71)
0.77 (0.51, 1.16)
1.10 (0.92, 1.32)
1.22 (0.84, 1.77)
0.90 (0.69, 1.18)
0.60 (0.36, 0.99)
1.11 (0.50, 2.48)
1.00 (0.51, 1.94)
0.62 (0.27, 1.43)
0.43 (0.26, 0.70)
0.98 (0.75, 1.28)
0.90 (0.80, 1.01)
0.86 (0.80, 0.93)
1.01 (0.88, 1.16)
1.00 (0.61, 1.63)
0.85 (0.78, 0.91)
Weight
1.7%
3.7%
1.8%
4.0%
0.8%
3.0%
1.5%
2.1%
4.9%
2.9%
3.2%
0.7%
2.7%
1.3%
2.1%
2.6%
0.8%
1.7%
4.3%
2.0%
3.0%
1.2%
0.5%
0.8%
0.5%
1.3%
3.0%
5.5%
6.3%
5.1%
1.3%
76.5%
OR (95% CI)
0.96 (0.87, 1.05)
0.89 (0.79, 1.00)
0.92 (0.61, 1.38)
0.70 (0.57, 0.86)
0.74 (0.49, 1.11)
0.82 (0.69, 0.97)
0.86 (0.77, 0.95)
Weight
6.0%
5.5%
1.8%
4.0%
1.7%
4.5%
23.5%Heterogeneity: Tau2 = 0.01; Chi2 = 9.56, df = 5 (p = 0.09), I2 = 48%
Test for overall effect: Z = 2.99 (p = 0.003)
0.85 (0.80, 0.90) 100.0%
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A
Figure 3. (a) Early age of menarche is associated with a higher risk of ER-positive breast cancer. (b) Early age of menarche is also
significantly associated with risk of ER-negative breast cancer, though the effect is not as strong as for ER-positive breast cancer.
OR was calculated using a random effects model to account for heterogeneity of study populations. The red squares and
horizontal black lines represent the ORs and 95% CIs for each study. The black diamond and its width represent the overall
effect estimate and the 95% CI. The vertical black line represents the null hypothesis (OR of 1). Premeno. = pre-menopausal,
Postmeno. = post-menopausal, cont. = continuous, ER = estrogen receptor, PR = progesterone receptor, TN = triple negative,
HER2 = human epidermal growth factor receptor 2, Lum. = Luminal, LE = less than or equal to, GE = greater than or equal to
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reproductive patterns were associated with ER
subtypes in ovarian cancer.
Breast and prostate cancer have a number
of similarities with regard to risk factors, tissue
physiology and evolutionary history [82]. Like breast
cancer, prostate cancer is characterized by both
hormone positive and hormone negative subtypes.
It has been suggested that certain aspects of mod-
ern environments may shape prostate cancer risk.
For example, modern dietary conditions may con-
tribute to both breast and prostate cancer risk
through similar mechanisms [82]. In addition to
modern nutritional conditions, it has been proposed
that modern social conditions may contribute to
prostate cancer susceptibility through upregulating
testosterone production [83]. Whether modern
reproductive patterns are risk factors for some
subtypes of prostate cancer and not others is an
open question.
Limitations and future directions
In our review and meta-analysis, we found that
ER-negative breast cancer susceptibility was not
associated with delayed reproduction and low parity,
while ER-positive breast cancer was associated with
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Subtotal (95% CI)
Total (95% CI)
Heterogeneity: Tau2 = 0.02; Chi2 = 69.31, df = 36 (p = 0.0007), I2 = 48%
Test for overall effect: Z = 2.42 (p = 0.02)
Test for subgroup differences: Chi2 = 1.91, df = 1 (p = 0.17), I2 = 47.7%
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Chinese, 20-70yo
Chinese, 20-70yo
American, 20-44yo
American, 20-44yo
Australian, 20-74yo
Canadian, premeno. 25-55yo
Canadian, postmeno. >55yo
American, 20-45yo
American, <57yo
American, <57yo
Canadian, premeno. <55yo
Canadian, postmeno. >55yo
American, 20-74yo
American, 20-74yo
Canadian, 20-69yo
American, 20-49yo
Australian, <40yo
Australian, <40yo
American, 25-54yo
American, 20-74yo
Vietnamese, Chinese premeno.
Swedish, postmeno. 50-70yo
Swedish, postmeno. 50-70yo
American, 40-80yo
American, 40-80yo
Chinese, 21-85yo
Chinese, 21-85yo
Polish, 20-74yo
Polish, 20-74yo
American
Japanese, >25yo
African American, 20-64yo
Population
Japanese, 40-59yo
American, postmeno. 50-79yo
American, 55-69yo
American, 55-69yo
American, 45-75yo
Comparison
LE 13 vs GE 17
LE 13 vs GE 17
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 14
LE 11 vs GE 14
LE 11 vs GE 14
8-12 vs GE 15
Cont. (2yr increments)
Cont. (2yr increments)
LE 12 vs GE 14
LE 12 vs GE 14
LE 11 vs GE 13
LE 11 vs GE 13
LE 11 vs GE 15
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 13
LE 13 vs GE 14
LE 14 vs GE 17
12-13 vs GE 16
12-13 vs GE 16
LE 11 vs GE 14
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
Cont. (2yr increments)
Cont. (2yr increments)
LE 12 vs GE 15
Cont. (2yr increments)
LE 12 vs GE 13
Comparison
Cont. (1yr increments)
LE 11 vs GE 14
LE 12 vs GE 13
LE 12 vs GE 13
LE 12 vs GE 15
Type
ER-PR-
ER-PR+
ER-PR+
ER-PR-
ER-
ER-PR-
ER-PR-
TN
TN
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ER-
ER-
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ER-PR-
ER-
ER-PR-
ER-PR-
ER-PR+
ER- 
TN
ER-
ER-PR-
ER-PR+
ER-PR-
ER-PR+
TN
HER2-overexpress.
HER2-overexpress.
TN
ER-
ER-
ER-
Type
ER-
TN
ER-PR-
ER-PR+
ER-PR-
OR (95% CI)
0.62 (0.46, 0.83)
0.77 (0.49, 1.20)
0.78 (0.61, 1.00)
0.87 (0.58, 1.30)
0.76 (0.34, 1.69)
1.12 (0.62, 2.03)
0.94 (0.64, 1.38)
0.40 (0.18, 0.89)
0.82 (0.63, 1.07) 
0.98 (0.81, 1.18)
1.75 (1.19, 2.58)
0.82 (0.48, 1.40)
0.91 (0.62, 1.33)
1.00 (0.51, 1.94)
0.71 (0.34, 1.49)
0.59 (0.38, 0.92)
0.80 (0.50, 1.29)
0.60 (0.40, 0.90)
0.56 (0.34, 0.93)
1.40 (1.07, 1.84)
0.87 (0.57, 1.34)
1.00 (0.59, 1.68)
0.80 (0.29, 2.22)
1.43 (0.76, 2.68)
0.56 (0.22, 1.43)
0.45 (0.18, 1.12)
0.65 (0.33, 1.28)
1.14 (0.86, 1.51)
0.78 (0.68, 0.89)
0.90 (0.77, 1.05)
1.06 (0.88, 1.28)
1.20 (0.69, 2.08)
0.88 (0.80, 0.97)
Weight
3.7%
2.3%
4.4%
2.6%
0.9%
1.5%
2.8%
0.9%
4.1%
5.2%
2.8%
1.8%
2.8%
1.3%
1.1%
2.3%
2.1%
2.6%
1.9%
4.0%
2.4%
1.8%
0.6%
1.4%
0.7%
0.7%
1.2%
3.9%
6.0%
5.7%
5.2%
1.7%
82.7%
OR (95% CI)
0.91 (0.79, 1.05)
0.96 (0.67, 1.38)
1.10 (0.70, 1.72)
1.10 (0.71, 1.71)
1.18 (0.88, 1.58)
0.97 (0.87, 1.09)
Weight
5.9%
3.0%
2.3%
2.3%
3.8%
17.3%
Heterogeneity: Tau2 = 0.00; Chi2 = 3.14, df = 4 (p = 0.53), I2 = 0%
Test for overall effect: Z = 0.45 (p = 0.65)
0.90 (0.83, 0.98) 100.0%
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Figure 3. Continued
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these commonly acknowledged risk factors. ER-
negative risk and ER-positive risk were both
associated with early menarche. This raises the
question of whether early menarche in ER-negative
and ER-positive breast cancer susceptibility is due to
different underlying mechanisms.
The present approach does not allow us to distin-
guish between a variety of potential mechanisms
that may underlie this differential effect of delayed
reproduction and low parity on ER-positive versus
ER-negative breast cancer. In future work, we plan
to examine potential mechanisms such as
upregulated inflammation and epigenetic factors
in ER-negative breast cancer susceptibility.
CONCLUSIONS
Despite general acceptance of the view that cyclical
hormone exposure leads to greater breast cancer
susceptibility and that factors like parity should
therefore be protective, our review of the literature
suggests that this view requires revision. Our meta-
analysis shows that modern reproductive patterns
are strongly associated with ER-positive breast can-
cer susceptibility but not ER-negative breast cancer
susceptibility. These results suggest that modern
humans may have higher rates of ER-positive breast
cancer (compared with ancestral humans) as a re-
sult of current reproductive patterns, including
lower parity, later age of first birth and earlier menar-
che. In contrast, ER-negative breast cancer is
associated only with earlier menarche, suggesting
that most aspects of modern reproductive patterns
are not contributing to ER-negative breast cancer
risk. This raises the possibility that ER-negative
breast cancer may have different mechanisms
underlying cancer initiation and promotion than
ER-positive breast cancer. It may be the case that
fundamental differences between ER-positive and
ER-negative breast cancers with regard to their risk
factors have often been overlooked because of
the inclusion of ER-negative breast cancers
(which are comparatively rare) with ER-positive
breast cancers in many studies of breast cancer risk
factors.
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APPENDIX: META-ANALYSIS METHODS
Search strategy
A literature search was conducted in PubMed (up
to August 2011) using the following search
string: ‘Breast Neoplasms’ AND (‘Receptor, erbB-2’
OR ‘Receptors, Estrogen’ OR ‘Receptors,
Progesterone’) AND (‘Parity’ OR ‘Reproductive
History’ OR ‘Parturition’ OR ‘Risk Factors’). The
citations of relevant articles were also evaluated
to identify additional studies that were not identified
bythePubMedsearch.Theabstractofeacharticlewas
used to identify studies that assessed reproductive
traits and determined the hormone receptor status
of the breast cancer. To be included, the study must
have reported a risk ratio (RR), OR or hazard ratio
(HR) and 95% CI for various reproductive traits. If
multiple studies were published on the same study
population, thelargerstudywasselected.Articlesthat
were ultimately reviewed were limited to those with a
case–control or cohort study design that had been
published in English.
Data extraction
Relevant data were extracted from each eligible
study, including the author’s last name, publication
year and country where the study was conducted,
measure of association, the 95% CI, the breast
cancer subtype and the menopausal status of the
subjects if the study population was restricted to a
certain subgroup. As breast cancer is a relatively rare
disease, the rare disease assumption applies, and
RRs, ORs and HRs were assumed to be equivalent.
If necessary, the RRs, ORs HRs and 95% CIs were
recalculated by taking the inverse of the published
value to make the baseline group (reference group)
consistent with other studies. If multiple results were
reported for the same exposure within the same
cohort, the data were prioritized in an effort to
prevent the same case population from being
included in the meta-analysis more than once.
If results from both unadjusted and adjusted
analyses were conducted, data from the adjusted
analyses were used. If the same study reported
associations for multiple breast cancer subtypes
(e.g. ER-positive, PR-positive, and ER-positive, PR-
negative), both results were included, as both
subtypes represent a different group of cases,
despite being compared with the same group of
controls. For the few studies that conducted both a
pooled analysis and one stratified by menopausal
status, only the results for the pooled analysis
were extracted, in keeping with how the majority of
studies handled their analyses. If the study only
reported stratified results or was restricted to pre-
or post-menopausal women only, the results were
included and the status specified in the figure. If
multiple ORs were reported for a multi-level
categorical comparison (e.g. 0 vs. 1 birth, 0 vs. 2
births and 0 vs. 3 births), only the most extreme
comparison was included. For the parity meta-
analysis, results were limited to those where the
baseline reference group was 0 births (nulliparous
women). The age at first birth analyses only
included results where there was at least a 10-year
difference between early and late age at first birth.
A minority of independent studies utilized data
from branches within a larger cancer registry (e.g.
the Surveillance, Epidemiology and End Results
(SEER) Program). Although it is possible that
studies that used this registry may include some of
the same breast cancer cases in their analyses, we
chose to include them as they often used a different
control base and modeling approaches. Among the
studies included, the age cutoff for early versus
late birth was typically 30 or 35, and the age cutoff
for early versus late menarche was typically around
12 years.
Statistical analysis
Given that the studies identified in the literature
search originated from many different countries,
time periods and populations with varying
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race/ethnicities and menopausal statuses, it was
assumed that there would be great heterogeneity
between the various study populations. For this
reason, random-effect models were used to
calculate summary ORs and 95% CIs.
A random-effect meta-analysis, as described by
DerSimonian and Laird [84], was used to combine
the results and generate a summary OR and
CI. The measures of association were extracted from
the publications and log ORs, and standard errors
were calculated and imported into the Review
Manager Version 5.2 software [85], which was
used for the statistical analyses and generation of
figures.
While one of the requirements of a meta-analysis
is to include one result per study, we felt that it was
important to report as many published results as
possible in order to display the breadth of the current
research. Based on our inclusion criteria, some
studies have multiple results included in the meta-
analysis dataset, such as results comparing two
different breast cancer subtypes to the same control
group within the same study. Consequently, this
may lead to artificially overconfident summary
measures because the model assumes that each
result originated from an independent study. The
95% CIs of the summary RRs may be too narrow
and the P-values are too small.
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